home / stock / bdsx / bdsx news


BDSX News and Press, Biodesix Inc. From 01/12/26

Stock Information

Company Name: Biodesix Inc.
Stock Symbol: BDSX
Market: NASDAQ
Website: biodesix.com

Menu

BDSX BDSX Quote BDSX Short BDSX News BDSX Articles BDSX Message Board
Get BDSX Alerts

News, Short Squeeze, Breakout and More Instantly...

BDSX - US Companies Moving the Markets, Evening edition
Mon, Jan 12, 2026 as of 4:00 pm ET

A look at the top 10 most actives in the United States Envirotech Vehicles Inc. (EVTV) rose 295.2% to $1.83 on volume of 610,320,780 shares Oriental Culture Holding LTD (OCG) fell 15.0% to $0.017 on volume of 389,655,949 shares Mingteng International Corporation Inc. (MTEN) fell 43.7% to $0...

BDSX - Morning Market Brief: Infrastructure, AI, and Biotech Signal a Scale-Up Cycle Is Underway

2026-01-12 08:59:15 ET Denver, Colorado- Markets are waking up to a familiar but powerful theme this morning: companies that spent years building quietly are now flipping the switch to scale. Across advanced materials, AI infrastructure, diagnostics, and biotech, today’s news flow hi...

BDSX - Biodesix skyrockets 43%, expects FY revenue to beat guidance

2026-01-12 07:17:30 ET More on Biodesix Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript Biodesix raises 2025 revenue guidance to $84M-$86M as primary care expansion accelerates Seeking Alpha’s Quant Rating on Biodesix Historical earnings data fo...

BDSX - Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (t...

BDSX - Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Clinical utility data for Nodify Lung ® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to...

BDSX - Biodesix raises 2025 revenue guidance to $84M-$86M as primary care expansion accelerates

2025-11-03 22:46:52 ET More on Biodesix Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript Biodesix, Inc. (BDSX) Q2 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on Biodesix Historical earnings data for Biodesix Financial infor...

BDSX - Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript

2025-11-03 22:46:23 ET Biodesix, Inc. (BDSX) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Scott Hutton - President, CEO & Director Robin Cowie - CFO, Secretary & Treasurer ... Read the full article on Seeking Alpha For f...

BDSX - Biodesix GAAP EPS of -$1.16 beats by $0.35, revenue of $21.8M beats by $0.82M

2025-11-03 16:10:48 ET More on Biodesix Biodesix, Inc. (BDSX) Q2 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on Biodesix Historical earnings data for Biodesix Financial information for Biodesix Read the full article on Seeking ...

BDSX - Biodesix Announces Third Quarter 2025 Results and Highlights

Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Co...

BDSX - Expected US Company Earnings on Monday, November 3rd, 2025

Hess Midstream LP Class A Representing Limited Partner Interests (HESM) is expected to report $0.73 for Q3 2025 IDEAYA Biosciences Inc. (IDYA) is expected to report $0 for Q3 2025 Unum Group (UNM) is expected to report $2.15 for Q3 2025 CNA Financial Corporation (CNA) is expected to r...

Previous 10 Next 10